A novel, topical, nonsteroidal, TRPV1 antagonist, PAC-14028 cream improves skin barrier function and exerts anti-inflammatory action through modulating epidermal differentiation markers and suppressing Th2 cytokines in atopic dermatitis

Atopic dermatitis (AD), also known as atopic eczema, is the most common inflammatory skin disease characterized by chronic and relapsing episodes of intense pruritus, an impaired epidermal barrier and eczematous lesions [1–3]. AD occurs more frequently in younger individuals; in the developing countries, prevalence ranges from 15% to 30% in children and 2% to 10% in adults [1,4]. Most of the patients develop AD in early childhood but late-onset AD can occur at all ages. The course is heterogeneous and unpredictable as some patients develop persisting or chronic relapsing AD, whereas others lose nearly all symptoms until adolescence [5,6].